Skip to main content

News & Events

Novozymes to Use Benson Hill’s Cpf1 and Cms1 Genome Editing Portfolio Across Its Business Segments

By Benson Hill

December 11, 2018


“Novozymes works with innovative customers across the globe to help them produce more from less, make their products stand out and reduce costs,” says Claus Crone Fuglsang, CSO and Senior Vice President, Research & Technology, Novozymes. “Benson Hill’s robust portfolio of gene editing nucleases and collaborative approach to empowering innovation aligns with our mission to leverage biological innovations and create new opportunities for our customers.” Read more from Seed Today here.


We’re empowering innovators to build the future of food production, and we’d love to have you be a part of it.

What’s your vision for the future?

Let’s build it together. Contact us to learn more about partnering with Benson Hill.